Month: March 2021

Mar 03 2021

Uncategorized

‘Landmark’ Schizophrenia Drug in the Wings?

by Clinical Editor

No Comments

A novel treatment that combines a muscarinic receptor agonist with an anticholinergic agent is associated with greater reduction in psychosis vs placebo, new research shows.

Mar 02 2021

Uncategorized

Clozapine Market: Rising cases of Schizophrenia and its Related Disorders to Drive the Market – BioSpace

by Clinical Editor

No Comments

Clozapine Market: Rising cases of Schizophrenia and its Related Disorders to Drive the Market  BioSpace

Mar 02 2021

Uncategorized

How Canadian Series ‘Son of Mine’ is Putting Schizophrenia Front and Center at Berlinale

by Clinical Editor

No Comments

When straight-A student Jacob (Antoine L’Ecuyer) starts hearing voices and howling wolves in his head, he blames it on a bad trip. However, he and his family are quickly forced...

Mar 02 2021

Uncategorized

Seeing schizophrenia: X-rays shed light on neural differences, point toward treatment

by Clinical Editor

No Comments

Schizophrenia, a chronic, neurological brain disorder, affects millions of people around the world. It causes a fracture between a person’s thoughts, feelings and behavior. Symptoms include delusions, …

Mar 02 2021

Uncategorized

The impact of creativity on functional outcome in schizophrenia: a mediational model

by Clinical Editor

No Comments

Functional impairment remains one of the most challenging issues for treatment in schizophrenia. However, previous studies have mainly focused on the negative impact of symptoms excluding variables …

Mar 02 2021

Uncategorized

UK Schizophrenia Drugs Market Size, Share, Growth, Research and Forecast 2020-2026

by Clinical Editor

No Comments

The MarketWatch News Department was not involved in the creation of this content. Mar 02, 2021 (Market Insight Reports) — UK schizophrenia drug market is projected to grow at a...

Mar 02 2021

Uncategorized

Phase II Results Promising for New Schizophrenia Drug Combo

by Clinical Editor

No Comments

Phase II results appear promising for a new combination treatment for schizophrenia. Findings from previous studies have shown that the muscarinic receptor agonist xanomeline could be used as a novel...

Mar 01 2021

Uncategorized

Seeing schizophrenia: X-rays shed light on neural differences, point toward treatment

by Clinical Editor

No Comments

Schizophrenia, a chronic, neurological brain disorder, affects millions of people around the world. It causes a fracture between a person’s thoughts, feelings and behavior. Symptoms include delusions, …

Mar 01 2021

Uncategorized

The impact of creativity on functional outcome in schizophrenia: a mediational model

by Clinical Editor

No Comments

Functional impairment remains one of the most challenging issues for treatment in schizophrenia. However, previous studies have mainly focused on the negative impact of symptoms excluding variables …

Mar 01 2021

Uncategorized

Childhood ADHD Increases Risk Of Developing Schizophrenia Or Other Psychotic Disorders

by Clinical Editor

No Comments

Childhood attention-deficit/hyperactivity disorder (ADHD) is linked to an increase risk of psychotic disorders such as schizophrenia, according to a recent study published in JAMA Psychiatry.